Peptibase
Weight Loss

Retatrutide

Also known as: LY3437943, Triple G

Clinical Trials
Share:

Key Facts: Retatrutide

Category
Weight Loss
FDA Status
Not FDA Approved
Clinical Status
Phase 3 Clinical Trials
Administration
Subcutaneous injection weekly
Typical Dose
4-12 mg weekly
Frequency
Once weekly, same day each week
Evidence Level
Human Trials
Duration
Long-term use expected
Also Known As
LY3437943, Triple G

What to Expect

A triple agonist targeting GLP-1, GIP, and glucagon receptors. Represents the next evolution beyond dual agonists like tirzepatide, showing unprecedented weight loss in trials.

Mechanism of Action

Retatrutide activates three receptors: GLP-1 for appetite suppression and glucose control, GIP for enhanced insulin response and metabolic effects, and glucagon for increased energy expenditure and fat oxidation. The triple mechanism provides synergistic effects.

Research Summary

Phase 2 trials showed up to 24% weight loss at 48 weeks, the highest seen in any obesity drug trial. Studies demonstrate significant improvements in metabolic markers, liver fat reduction, and glycemic control. Phase 3 trials underway.

Clinical Status:Phase 3 Clinical Trials
Trial Progress:Phase III
Pre
I
II
III
IV
FDA

Dosing Information

Human Trials·Human studies conducted, not FDA approved

Typical Dosingⓘ

Community experience

Common Dose

4-12 mg weekly

Range

1-12 mg weekly (titrate up slowly)

Frequency

Once weekly, same day each week

Triple agonist (GLP-1/GIP/glucagon). Start low (1-2 mg) and titrate up to minimize GI side effects. Not yet FDA approved but available through compounding.

Research Dosingⓘ

Scientific studies

Doses from clinical trials

Duration

Long-term use expected

Administration

Subcutaneous injection weekly

Timing & Administration

Best Time to Take

Morning, same day each week

Once weekly, same day and time

Food Recommendation

With or without food

Why This Timing?

As a triple agonist, consistent weekly timing is important. Morning allows for side effect monitoring.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Nausea (dose-related)
  • ●Diarrhea
  • ●Vomiting
  • ●Constipation
  • ●Heart rate increases
  • ●Hypersensitivity reactions
  • ●Pancreatitis (rare)
  • ●Currently in Phase 3 trials

References

Related Peptides

Peptides commonly compared with Retatrutide or used in similar applications.

Semaglutide

FDA

A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. One of the most effective pharmaceutical weight loss interventions available.

Weight Loss

Tirzepatide

FDA

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials.

Weight Loss

Orforglipron

Clinical Trials

An oral non-peptide GLP-1 receptor agonist. Could provide injection-free alternative to semaglutide and tirzepatide.

Weight Loss

CagriSema

Clinical Trials

A combination of semaglutide and cagrilintide (amylin analog) in development. Aims to provide superior weight loss through dual mechanisms.

Weight Loss

Survodutide

Clinical Trials

A dual GLP-1/glucagon receptor agonist in development for obesity and NASH. Combines appetite suppression with increased energy expenditure.

Weight Loss

Cagrilintide

Clinical Trials

A long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).

Weight Loss
How to Use RetatrutideRetatrutide AlternativesCompare with SimilarBrowse All Peptides

Want updates on Retatrutide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Educational Information Only

This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.

Back to all peptides